Kessler Topaz Meltzer & Check, LLP - ADMA Biologics, Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The complaint alleges the company engaged in channel stuffing, undisclosed related party transactions, and lacked adequate internal controls. The stock dropped 29.1% following a Culper Research report exposing these practices. Investors who purchased securities between August 9, 2024 and March 25, 2026 can seek lead plaintiff status by August 10, 2026.